article thumbnail

Fresenius Kabi and Formycon Reach Settlement Agreement for Ustekinumab Biosimilar Candidate in Europe and Canada

JD Supra Law

On March 18, 2024, Fresenius Kabi (“Fresenius”) and Formycon announced a settlement agreement with Johnson & Johnson regarding FYB202, a proposed ustekinumab biosimilar to STELARA in Europe and Canada. The terms of the settlement are confidential. By: Goodwin

article thumbnail

Sebi’s Shift towards the T+0 Settlement System

IP and Legal Filings

Introduction Recently on 28 th March 2024, India’s stock market-initiated T+0 settlement system which is world’s fastest stock settlement system. The same day transaction settlement i.e. T+0 is launched for a select few cash segment stocks. This settlement is particularly aimed at accelerating the trade settlement cycle.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Stelara® Biosimilar Updates: Settlement of IPR and FDA Review of Proposed Biosimilar

JD Supra Law

On March 4, 2024, the PTAB granted Biocon and Janssen’s joint motion to terminate IPR2023-01444 due to a settlement reached prior to an institution decision. by February 2025, subject to FDA approval.

article thumbnail

USPTO Issues Notice of Proposed Rulemaking On Discretionary Denial, Serial and Parallel Petitions, and Settlement

JD Supra Law

On April 19, 2024, the USPTO issued a Notice of Proposed Rulemaking (the “Notice”) regarding discretionary denial in post-grant proceedings and other issues. Topics include a new procedure for patent owners to request discretionary denial, institution of serial and parallel petitions, and pre-institution settlement agreements.

article thumbnail

Latest Federal Court Cases - January 2024 #2

JD Supra Law

3, 2024) In our Case of the Week, the Court of Appeals for the Federal Circuit affirmed a district court’s denial of DexCom’s motion to preliminarily enjoin Abbott from proceeding with its inter partes review challenges to DexCom’s patents, based on a “no challenge” provision in a prior settlement agreement between the parties.

article thumbnail

Patent Case Summaries | Week Ending January 5, 2024

JD Supra Law

After years of patent litigation, they entered into a settlement and license agreement. Abbott Diabetes Care, Inc., 2023-1795 (Fed. Opinion by Stoll, joined by Dyk and Hughes. DexCom and Abbott are competing manufacturers of continuous glucose monitoring systems.

article thumbnail

Stay ADvised: 2024, Issue 3

JD Supra Law

It recently announced separate settlements against companies accused of assisting telemarketers to make prerecorded messages or calls to numbers on the Do Not Call (DNC) list. In its ongoing action focused on robocalls, the Federal Trade Commission (FTC) is taking steps against two companies that make robocalls possible.